Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.